Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Reuters

06-21

Structure <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions

Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2545105283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2545105283\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2545105283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-21 07:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545105283","market":"fut","top_or_hot":-1,"title":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. <a href=\"https://laohu8.com/S/GPCR\">$(GPCR)$</a>, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStructure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-21 07:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Structure <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Structure Therapeutics Inc. <a href=\"https://laohu8.com/S/GPCR\">$(GPCR)$</a>, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2210149790.SGD","symbol_name":"Natixis Thematics Subscription Economy R/A SGD-H","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250620:nNDL20pdcm:1","article_id":"2545105283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545105283","pubTimestamp":1750462216,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on June 20, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","BK4599":"减肥药","BK4007":"制药","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC"},"translate_title":"Structure Therapeutics Inc.在ADA科学会议上公布了口服小分子胰淀素激动剂ACCG-2671的有希望的临床前数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GPCR":0.9,"NDAQ":0.9},"content_text":"Structure Therapeutics Inc. Unveils Promising Preclinical Data for Oral Small Molecule Amylin Agonist ACCG-2671 at ADA Scientific Sessions\n    \n\n        Structure Therapeutics Inc. $(GPCR)$, a clinical-stage global biopharmaceutical company, announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, taking place from June 20-23, 2025, in Chicago, IL. The presentations will include new preclinical data on ACCG-2671, an oral small molecule amylin agonist, which is expected to enter clinical development by the end of 2025. The preclinical studies highlighted significant weight-loss effects of ACCG-2671 alone and in combination with a GLP-1 receptor agonist in diet-induced obese rats. Additionally, data on a GLP-1 receptor agonist, GSBR-5595, will be presented, demonstrating neuroprotective effects in a Parkinson's disease mouse model. These findings will be shared on June 22, 2025, during the Late Breaking Poster Session at the event.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9472134-en) on June 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}